Less than ideal: how oncologists practice with limited drug access
Kelvin K Chan1, Bertha Wong, Lillian L Siu
1Sunnybrook Odette Cancer Centre; Princess Margaret Hospital, University Health Network; University of Toronto; Li Ka Shing Knowledge Institute of St. Michael's Hospital; and RS McLaughlin Durham Regional Cancer Centre, Oshawa, Toronto, Ontario, Canada.
Canadian oncologists face challenges accessing new cancer drugs, impacting patient care for metastatic colorectal cancer. Many support private payment and a national formulary due to funding and approval process concerns.
Area of Science:
- Oncology
- Health Services Research
- Pharmacoeconomics
Background:
- Access to novel, expensive cancer therapeutics is a growing concern in clinical practice.
- Barriers to drug access can significantly influence treatment decisions and patient outcomes.
- Understanding oncologists' perspectives is crucial for improving drug approval and funding processes.
Purpose of the Study:
- To evaluate Canadian medical oncologists' perspectives on barriers to accessing new, expensive cancer drugs.
- To assess the impact of these barriers on their clinical practice.
- To understand their opinions on current drug approval and funding mechanisms.
Main Methods:
- A cross-sectional survey was administered to Canadian medical oncologists treating colorectal cancer (CRC).
- The survey used a self-administered questionnaire to gather data on practice patterns and opinions.
- Data were collected from a sample of eligible oncologists, with a 41.4% response rate.
Main Results:
- Only 29.4% of oncologists felt they could provide the ideal first-line chemotherapy for metastatic CRC.
- Despite bevacizumab's recognized importance, only 18% could use it routinely.
- Physicians expressed significant concerns (97%) about drug approval/funding and supported (85%) a national drug formulary.
Conclusions:
- Canadian oncologists struggle to deliver optimal care for metastatic CRC due to unequal access to preferred drugs.
- Physicians resort to clinical trials and private clinics, sometimes withholding discussions about drugs with limited access.
- Dissatisfaction with current funding and approval processes is high, with support for private payment for unfunded drugs.
Related Concept Videos
Treatment Resistent Cancers
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's cancer...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

